It has been demonstrated that susceptibility to palbociclib treatment in breast cancer may be predicted by immunohistochemical identification of Thr172-phosphorylated CDK4 (an activating phosphorylation performed through the CDK-activating kinase, CAK). Here, CDK4 is linked to breast cancer.